Reply To: Lesson 10

1) The PrEP example in Module 10 highlighted how product introduction and scale-up can differ according to factors such as the country’s health systems, regulatory approval processes, and the availability of financial, human and other resources. Reflect on your setting and think about the potential process for introduction and possible scale-up of an efficacious microbicide (e.g., tenofovir gel or dapivarine ring). Describe what might be similar or different to the PrEP timeline
Refer to The World Health Organisation in 2012, published guidance on the use of PrEP for serodiscordant couples, and men and transgender women who have sex with men. Specifically the HIV-negative partner of a serodiscordant. .
It has been argued that pre-exposure prophylaxis could have an enormous impact on the worldwide HIV epidemic. Mathematical models estimate that if tenofovir PrEP was used by 90 percent of high-risk people and was effective 90 percent of the time, potentially the spread of HIV infection could be reduced by more than 80 percent in a few years. However in THAILAND, If anyone interest to use PrEP, they need to pay by themselves. In the Future, hope policy could be prevented HIV infection by using PrEP and preventing high-risk behaviours among the most sexually active population groups.
2) Describe ways you have engaged stakeholders (or been engaged as a stakeholder) in results dissemination for a trial and/or possible future access of a trial product. What were some of the challenges? Are there lessons learned you might share?
I never involved in PrEP trial but I think it is importance to sharing large trial results, in language that all stakeholders can understand, regardless of their background in science and, specifically, the science behind the trial product.